Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert Jon Soiffer, M.D.

Co-Author

This page shows the publications co-authored by Robert Soiffer and Rizwan Romee.
Connection Strength

1.165
  1. Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Adv. 2021 01 26; 5(2):352-364.
    View in: PubMed
    Score: 0.236
  2. Defibrotide: Real World Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Stem Cell Transplant. Blood Adv. 2021 Oct 19.
    View in: PubMed
    Score: 0.062
  3. Adding venetoclax to fludarabine/busulfan RIC transplant for high risk MDS and AML is feasible, safe, and active. Blood Adv. 2021 Oct 06.
    View in: PubMed
    Score: 0.062
  4. Impact of Cryopreservation and Transit Times of Allogeneic Grafts on Hematopoietic and Immune Reconstitution. Blood Adv. 2021 Sep 28.
    View in: PubMed
    Score: 0.062
  5. Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience. Transplant Cell Ther. 2021 Sep 02.
    View in: PubMed
    Score: 0.062
  6. Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. Haematologica. 2021 Aug 26.
    View in: PubMed
    Score: 0.061
  7. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood. 2021 07 22; 138(3):273-282.
    View in: PubMed
    Score: 0.061
  8. Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplant. 2021 May; 56(5):1217.
    View in: PubMed
    Score: 0.060
  9. HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. Blood. 2021 Apr 13.
    View in: PubMed
    Score: 0.060
  10. Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2021 06; 27(6):479.e1-479.e7.
    View in: PubMed
    Score: 0.059
  11. COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Adv. 2021 02 09; 5(3):861-871.
    View in: PubMed
    Score: 0.059
  12. Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Adv. 2020 09 08; 4(17):4113-4123.
    View in: PubMed
    Score: 0.057
  13. Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplant. 2021 05; 56(5):1006-1012.
    View in: PubMed
    Score: 0.057
  14. BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. Blood Adv. 2020 05 12; 4(9):1881-1893.
    View in: PubMed
    Score: 0.056
  15. Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 03; 26(3):529-539.
    View in: PubMed
    Score: 0.054
  16. Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch? Blood Adv. 2018 06 12; 2(11):1180-1186.
    View in: PubMed
    Score: 0.049
  17. Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2017 Sep 10; 35(26):3002-3009.
    View in: PubMed
    Score: 0.046
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.